Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kyntra Bio (KYNB) EBT Margin (2016 - 2025)

Historic EBT Margin for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to 1221.75%.

  • Kyntra Bio's EBT Margin rose 380376000.0% to 1221.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 347.55%, marking a year-over-year increase of 130000.0%. This contributed to the annual value of 2130.1% for FY2024, which is 14395000.0% down from last year.
  • According to the latest figures from Q3 2025, Kyntra Bio's EBT Margin is 1221.75%, which was up 380376000.0% from 1021.88% recorded in Q2 2025.
  • Kyntra Bio's 5-year EBT Margin high stood at 126.16% for Q4 2023, and its period low was 39259.35% during Q3 2024.
  • Moreover, its 5-year median value for EBT Margin was 647.06% (2022), whereas its average is 3497.47%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -390993700bps in 2024, then skyrocketed by 380376000bps in 2025.
  • Over the past 5 years, Kyntra Bio's EBT Margin (Quarter) stood at 811.88% in 2021, then surged by 76bps to 193.05% in 2022, then surged by 165bps to 126.16% in 2023, then tumbled by -64bps to 44.92% in 2024, then plummeted by -2820bps to 1221.75% in 2025.
  • Its last three reported values are 1221.75% in Q3 2025, 1021.88% for Q2 2025, and 931.33% during Q1 2025.